Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.

"Conflict-of-interest disclosure: L.C., Y.Q., and Z.C.X. are employees of ADC Therapeutics with equity and stock options in the company. L.L. and Y.W. report equity and stock options in ADC Therapeutics and were affiliated with ADC Therapeutics at the time the work was conducted. B.K. has received consulting fees from ADC Therapeutics. A. Spira has received institutional research support from ADC Therapeutics. J.R. has received honoraria from ADC Therapeutics for taking part in advisory boards and is an ADC Therapeutics stockholder. P.F.C. reports grants from ADC Therapeutics, during the conduct of the study; grants and personal fees from Genentech; and personal fees from ADC Therapeutics, Amgen, Celgene, Kite Pharmaceuticals, Seattle Genetics, TG Therapeutics, and Verastem, outside of the submitted work. W.A. reports grants from Nurix Therapeutics and personal fees from ADC Therapeutics, Kymera, and Nurix outside of the submitted work. K.M.A. reports clinical research support from University College London Hospitals Biomedical Research Centre, and personal fees from BeiGene, Celgene, Gilead, Roche, and Takeda outside of the submitted work. M.H. reports grants from Astellas Pharma, Spectrum Pharmaceuticals, and Takeda, and personal fees from AbGenomics, ADC Therapeutics, AstraZeneca, BeiGene, Celgene, Incyte Corporation, Janssen, Omeros, Pharmacyclics, Sanofi Genzyme, TeneoBio, and Verastem outside of the submitted work. B.H. reports grants from ADC Therapeutics during the conduct of the study, and personal fees from ADC Therapeutics, AstraZeneca, and Bristol Myers Squibb outside of the submitted work. M.S. reports grants from ADC Therapeutics during the conduct of the study, and personal fees from Amgen and Celgene outside of the submitted work. A. Stathis reports grants from ADC Therapeutics during the conduct of the study; grants from Bayer, Eli Lilly, MEI Pharma, Merck, Novartis, Pfizer, and Roche; and personal fees from AbbVie and PharmaMar outside of the submitted work. P.L.Z. reports personal fees from ADC Therapeutics, Bristol Myers Squibb, Celgene, Celltrion, Eusapharma, Gilead, Immune Design, Janssen-Cilag, Kyowa Kirin, Merck Sharp & Dohme, Portola, Roche, Sandoz, Sanofi, Servier, and Verastem outside of the submitted work. C.C.-S. reports grants from ADC Therapeutics during the conduct of the study; grants from Rhizen Pharmaceuticals; and personal fees from ADC Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genenta Science, Janssen Oncology, Karyopharm, Merck Sharp & Dohme, Novartis, Roche, Sanofi, and Servier outside of the submitted work. J.P.A. reports personal fees from ADC Therapeutics and Genentech outside of the submitted work, and has an immediate family member who has served on advisory boards from Agios Pharmaceuticals, Forma Therapeutics, Foundation Medicine, Inovio Pharmaceuticals, and Puma Biotechnology. X.Z. declares no competing financial interests."

"Medical writing support was provided by Loren M. DeVito of Citrus Health Group, which was in accordance with Good Publication Practice (2022) guidelines and funded by ADC Therapeutics SA (Murray Hill, NJ). The LOTIS-2 (ADCT-402-201) study was funded by ADC Therapeutics SA."